Skip to main content

Repetitive transcranial magnetic stimulation treatment for peripartum depression: systematic review & meta-analysis



Peripartum depression is a common disorder with very high potential hazards for both the patients and their babies. The typical treatment options include antidepressants and electroconvulsive therapy. However, these treatments do not ensure the safety of the fetus. Recently, repetitive transcranial magnetic stimulation has emerged as a promising treatment for neuropathies as well as depression. Nevertheless, many studies excluded pregnant women. This systematic review was conducted to confirm whether repetitive transcranial magnetic stimulation was a suitable treatment option for peripartum depression.


We performed a systematic review that followed the PRISMA guidelines. We searched for studies in the MEDLINE, PsycINFO, EMBASE, and Cochrane library databases published until the end of September 2020. Eleven studies were selected for the systematic review, and five studies were selected for quantitative synthesis. Data analysis was conducted using Comprehensive Meta-Analysis 3 software. The effect size was analyzed using the standardized mean difference, and the 95% confidence interval (CI) was determined by the generic inverse variance estimation method.


The therapeutic effect size of repetitive transcranial magnetic stimulation for peripartum depression was 1.394 (95% CI: 0.944–1.843), and the sensitivity analysis effect size was 1.074 (95% CI: 0.689–1.459), indicating a significant effect. The side effect size of repetitive transcranial magnetic stimulation for peripartum depression was 0.346 (95% CI: 0.214–0.506), a meaningful result. There were no severe side effects to the mothers or fetuses.


From various perspectives, repetitive transcranial magnetic stimulation can be considered an alternative treatment to treat peripartum depression to avoid exposure of fetuses to drugs and the severe side effects of electroconvulsive therapy. Further research is required to increase confidence in the results.

Peer Review reports


Peripartum depression (PPD) is defined as major depression occurring within the gestational period and 4 weeks after childbirth [1]. PPD is a common disease that 10 ~ 15% of pregnant women experience (, and PPD patients incur a massive lifetime expense of 75,728 pounds (USD $95,656) [2]. PPD threatens not only the mother’s health by causes hormonal imbalance [3], alcohol and substance abuse [4], and more than 5-fold increased maternal suicide [5]. The health of the fetus is also affected by premature birth (the effect size of peripartum depression on premature birth is 1.38) [6], and low birth weight (the effect size of peripartum depression on low birth weight is 1.3) [7]. PPD also interferes with creating a stable attachment in infants ‘growth process, which can result in self-control and cognitive function behavioral issues [8].

The methods for treating PPD are mainly electroconvulsive therapy (ECT) and antidepressants [9]. Although both have proven treatment effectiveness for PPD [10,11,12,13], some concerns for the safety of pregnant women and fetuses have been raised. Antidepressants relieve depression by regulating the neurotransmitters that make people feel happy [14]. Neurotransmitters released from pre-synaptic neurons are reabsorbed or decomposed by monoamine oxidase enzymes to transfer them to the neurons from the synapses Antidepressants reduce neurotransmitter decomposition by interfering with their reabsorption and the activity of monoamine oxidase enzymes, thereby alleviating depression [15]. Antidepressants are one of the most used treatment methods for PPD, but there are some concerns. Because components of antidepressants can pass through the placenta [16], these could have a chemical effect on the fetus. Pregnant women taking SSRI have a 7-fold increased risk of spontaneously induced abortion [17, 18], more than 3-fold increased risk of fetal infections [19], and increased risks of premature birth and underweight babies [20], autism spectrum disorder in the baby [21], increased risk of motor, speech, and scholastic disorder [22], cardiac defects [23] and persistent pulmonary hypertension [24]. Also, infants can be exposed to antidepressants and their metabolites during breastfeeding [25], which could increase monoamine oxidase levels and affect the functional maturity of the infant’s brain [26]. Side effects, such as decreased feeding [27], colic, and irritability [28] have been reported. Another treatment, ECT, is delivering a stimulating electrical shock to the brain to relieve depression. Electric shocks affecting neurons and chemicals in the brain produce short and controlled seizures, which have excellent effects on various neurological disorders [29]. However, treating pregnant women with ECTs can cause adverse effects such as vaginal bleeding and miscarriage [30], uterine contractions [31], abdominal pain [32], and preeclampsia [33]. Clinicians recommend these treatments because the risk of the treatment is smaller than the risk of PPD [34, 35] and their effectiveness has been proven. However, considering these treatment’s safety concerns for the fetus and mother, research to identify safer treatment methods is needed.

With the recent development in brain stimulation research, many researchers are increasingly trying to use brain stimulation for various neurological treatments [36]. One type of brain stimulation, repetitive transcranial magnetic stimulation (rTMS), stimulates the brain’s dorsolateral prefrontal cortex (DLPFC) with magnetic fields to induce the degeneration of neurons and activate the neural system of the brain to relieve depression [37]. Using rTMS to treat PPD is still reluctant [38,39,40], although studies have shown that rTMS is safe [41] and effective for treating several neurological diseases [42,43,44].

Thus, in this paper, we conducted a systematic review and meta-analysis to confirm whether rTMS treatment was suitable for PPD. There are few systematic review studies on rTMS treatment for PPD [45,46,47,48], but no studies statistically analyzed the therapeutic effects and safety and considered the adverse effects on fetuses. To investigate these problems, we conducted a meta-analysis to confirm the effect size of the therapeutic effects and safety and extended the range of patients from pregnant patients to 1 year after childbirth to identify the effect on the fetuses.


The systematic review followed the PRISMA guidelines (registration number CRD42020197855) [49].

Key questions

The criteria used in selecting the relevant studies included patients from the pregnancy period to 1 year after childbirth, intervention with TMS, no limits on the comparators, and outcomes measured by the degree of depression alleviation. The detailed key questions were:

(1) Is rTMS effective for PPD? What is the effect size of rTMS for PPD?

(2) Does rTMS have maternal and fetal side effects? What is the effect size of the side effects caused by rTMS?

Inclusion and exclusion criteria

In general, the studies used for the meta-analysis were randomized controlled trials (RCTs), but non-randomized studies (NRS) were also included in the meta-analysis, and case studies were included in the systematic review because only a small number of randomized trials provided evidence of the effects of the interventions [50] associated with pregnancy. Before inclusion, the non-randomized studies were evaluated to verify that the patients, interventions, comparisons, and outcomes were set appropriately by the Cochrane algorithm. If systematic reviews or meta-analyses were included, we checked the included studies and references. The criteria for exclusion were (1) experimental studies with animals, (2) studies not published in English, (3) studies that were not original (if there was only abstract, the original text was requested in an e-mail to the author), (4) symptoms of baby blues or postpartum psychosis, and (5) major depressive disorder that did not occur from pregnancy to 1 year after childbirth.

Literature search strategy

We performed a literature search of studies published before the end of September 2020 using EMBASE, MEDLINE, PsycINFO, and the Cochrane Library. In the literature search, the medical indications and treatment methods were searched using Boolean models. The indications search terms were using peripartum depression or antepartum depression or postpartum depression or pregnancy or perinatal, and the treatment searches were using rTMS or repeated transcranial magnetic stimulation or TMS or transcranial magnetic stimulation. If there were mapping or mesh term, it was used, otherwise it was extensive mode. The detailed search strategies are presented in Fig. 1. To minimize the omission of data and increase reliability, HJL, and JYK independently reviewed the literature and, if the opinions of the researchers differed, the studies were reviewed together, and an agreement was reached.

Fig. 1

Searching strategy

Data extraction

For the final selected literature, the following data were extracted: basic information (the title of paper, author, year of publication), study characteristics (study design, number of subjects), subject information (age, primary psychiatric diagnosis, gestational age, and simultaneous treatment), treatment parameters (motor threshold, site of stimulation, frequency and pulse, interval time, number of sessions) [51] and the result (outcome measure at baseline and at the end of treatment, side effects on mothers and fetuses).

Risk of bias assessment

After the literature screening, a bias evaluation of the studies was performed by two evaluators independently to clarify ambiguous differences between the reporting quality and research quality. Different evaluation methods were applied according to the study design. RCT studies were examined using the risk-of-bias 2 (ROB2) tool [52], and the NRS were examined using the Risk of Bias Assessment Tool for Non-randomized Studies (ROBINS-I) [53]. Case reports and series were evaluated used the methodological quality tool [54] because they could be adopted as evidence of new treatments [55]. The final judgment on the overall risk of bias was agreed upon between the two evaluators, and publication bias was visually reviewed through funnel plots, and additionally, statistically confirmed through Egger’s regression.

Data analysis

Data analysis was conducted using Comprehensive Meta-Analysis 3 software (CMA3). The effect size was used standardized mean difference (SMD) was obtained using two-group, pre-post data in the RCTs, and one group pre-post data for the NRS [56]. For the 95% CI and the correlation coefficient value of 0.5, the generic inverse variance estimation method was used [57]. Safety was assessed using the effect size of the side effects, and the effect size was calculated by the same method as the treatment effect. The calculations are presented as a Forest plot. Heterogeneity was determined using the statistical test method Cochrane’s Q test and the I-squared (I2) statistic. If the p-value of the Q test value exceeded 0.1 and the I2 statistic exceeded 50%, a random-effects model was applied, and if the Q test value was less than 0.1 and the I2 statistic was less than 50%, a fixed-effects model was applied.


Search results

We conducted a literature search following the PRISMA FLOW guidelines (Fig. 2). Of the 229 studies identified in the database, 128 remained after the removal of the duplicates. Ninety-eight studies were excluded because they did not meet the inclusion and exclusion criteria. We performed a full-text review of 30 studies to confirm whether they were suitable for our research purposes. Finally, 10 studies suitable for the systematic review, and five studies suitable for meta-analysis were selected to confirm the therapeutic effect and safety of rTMS. The detailed of exclude studies and reason is presented Additional files 1. There were three studies with only abstracts, so we requested the original text by email, but no author responded.

Fig. 2

Study Selection PRISMA flow diagram

Characteristics of the selected studies

Eleven studies identified the efficacy and safety of rTMS for PPD, two RCT studies [58, 59], four NRS [60,61,62], and five case studies [63,64,65,66,67]. One NRS study was excluded from the meta-analysis since the study did not report detailed outcomes. The total number of participants was 101, 84 of whom received active rTMS treatment. During pregnancy, 65 patients were treated with rTMS, and most of them were in the second and third trimesters of pregnancy. Seventeen patients were treated for postpartum depression, and two patients were treated during pregnancy and after delivery. Although 20 participants were treated with antidepressants [60, 61, 65] along with rTMS, their antidepressant doses were stable for two to 4 weeks, and one participant was treated with clonazepam for insomnia [62]. The treatment parameters and protocols in each study were all different, which seemed to be because the protocol for TMS therapy for perinatal depression has not yet been accurately established. Twenty-two patients were stimulated to the right DLPFC [58, 60, 65, 66], 79 to the left DLPFC [59, 61,62,63,64,65], and the patients in one studies [65] were stimulated on both sites. The patients who were stimulated on the right DLPFC showed symptoms of anxiety and were treated with a frequency of less than 1 Hz, which is relatively less than that used to stimulate the left DLPFC (more than 5 Hz). The researchers considered the interval time and duration of stimulation to minimize side effects such as seizures and did not show any common characteristics for the other treatment parameters. The detailed are presented Tables 1, 2, and 3.

Table 1 Characteristics of the subjects in the included studies
Table 2 Characteristics of the treatments in the included studies
Table 3 Characteristics of the outcomes in the included studies

Therapeutic effects

In the 10 studies selected for the systematic literature review, 76 patients had an average 59% improvement in depression. Thirty-seven percent of the participants showed depression remission (depression scale rating was lowered to that of a normal person), and 66% of the participants showed a response to rTMS (depression scale score reduced more than 50% compared to before treatment). In Kim’s study [58], one of the RCT studies, 45.45% of the control group responded, whereas 81% of the experimental group responded, and the remission rate also showed a significant difference of 9% or more between the experimental group and the control group. Another RCT study also showed a difference in the depression scale of about 23% between the control group and the experimental group, showing a similar treatment effect to that of antidepressants [59]. In the NRS, the response rate of 56 participants was 33%, and the remission rate was 59%. In the study by Garcia et al. [62], the depression scale scores showed that all participants achieved remission, and all except one participant responded to rTMS. The other NRS also showed treatment effects, and in the case study, all nine participants responded to rTMS. All studies showed treatment effectiveness, but treatment effectiveness declined as the study design was refined.

Evaluation of the heterogeneity of the studies for treatment effects showed a p-value of < 0.001 and an I 2 statistic of 71.933. Because the I 2 statistic exceeded 50%, a random-effects model was applied (Fig. 3). The effect size of rTMS for PPD had an SMD of 1.394 (95% CI: 0.944–1.843), indicating a significant treatment effect (Z = 6.079, p < 0.01).

Fig. 3

Forest plot of therapeutic effects. Abbreviations: BAI: Beck Anxiety Inventory; BDI: Beck Depression Inventory; CGI-S: Clinical Global. Impression Scale; EPDS: Edinburgh Postnatal Depression Scale; HDRS: Hamilton Depression. Rating Scale; GAS, Global Assessment Scale; SF-36-V and SF-36-MH: 36-item Quality of Life. Health Survey, Vitality, and Mental Health scores; IDS-SR: Inventory of Depressive. Symptomatology-Self-Report

Figure 4 shows the sensitivity analysis performed because we thought that the treatment effect in one study [62] was measured too high. Excluding this, the heterogeneity showed a p-value of < 0.01 and an I2 statistic of 62.593, and because the I2 value exceeded 50%, a random-effects model was applied. The effect size of rTMS for PPD had an SMD of 1.074 (95% CI: 0.689–1.459), indicating a meaningful treatment effect (Z = 5.468, p < 0.01). The sensitivity analysis showed that the heterogeneity decreased, but the I2 value still exceeded 50%, and the treatment effect was also slightly reduced, but the treatment effect was still significant.

Fig. 4

Forest plot of the sensitivity analysis Abbreviations: BAI: Beck Anxiety Inventory; BDI: Beck Depression Inventory; CGI-S: Clinical Global. Impression Scale; EPDS: Edinburgh Postnatal Depression Scale; HDRS: Hamilton Depression. Rating Scale; GAS, Global Assessment Scale; SF-36-V and SF-36-MH: 36-item Quality of Life. Health Survey, Vitality, and Mental Health scores


In the 10 studies selected for systematic review, about 15% of the patients experienced side effects in the group receiving rTMS therapy. However, in the RCTs, there was no difference between the experimental groups and the control groups [58, 59], and there were minor side effects that did not worsen the patients’ health, such as headache [58, 60, 62, 65, 66] and pain at the stimulation site [62, 66]. Supine hypotension syndrome was reported as an adverse event in some mothers [60]. However, this is a disorder caused by posture during treatment and can be prevented after posture correction [68]. The side effects in the infants included preterm birth, and five fetuses experienced preterm birth, but all of the fetuses were healthy. Brachial plexus injury was reported as an adverse event in one fetus, but it was caused by the large shoulder of the fetus and was not a side effect of the treatment process [58].

Evaluation of the heterogeneity of the studies for the side effects showed a p-value of < 0.01 and an I2 value of 46.631 and, because the I2 value was less than 50%, a fixed-effects model was applied (Fig. 5) The effect size of side effects had an SMD of 0.346, (95% CI: 0.214–0.506), indicating that rTMS had an effect on the occurrence of side effects (Z = − 1.889, p = 0.059).

Fig. 5

Forest plot of the side effects

Risk of bias

According to the experimental design, the RCTs were evaluated by ROB2, the NRS by ROBIN-I, and the case studies were evaluated using a methodological quality tool. We evaluated the bias according to the guidance of the tool and assessed the overall bias as a low risk of bias if all domains of bias were low risk, a high risk of bias if there were one or more high-risk domains or many suspected risks (Fig. 6). In the case of Myczkowski’s study [58], the study could have selective reporting bias because the planned outcomes were selectively reported. Bias in the outcomes measurements in the NRS was evaluated as moderate [60,61,62] because the study design of all of the NRS was open-label, meaning that the patients knew their treatment, and the risk of bias in Garcia’s study [62] was evaluated as high because there were missing data, which could have a significant impact on the outcome. The overall evaluation of bias was moderate, but this must be considered as it can cause over or underestimation of the effect sizes. The detailed risk of bias assessment for the domains is presented in Additional files 2.

Fig. 6

Risk of bias graphs: a RCT risk of bias, b NRS risk of bias, and c case study risk of bias

Figure 7 is a funnel plot showing the relationship between the sample size and the effect size to confirm publication bias. We visually checked whether the funnel plot was symmetrical and checked Egger’s regression to determine statistically significant. Publication bias existed because the funnel plot was not symmetric and had a p-value of 0.01. However, without Garcia’s study [62], which had a high risk of bias, the funnel plot had a symmetrical structure and a p-value of 0.121, so it can be said that there was no publication bias. In the case of safety, since there were fewer than 10 documents included, the minimum conditions for publication bias were not satisfied, and the publication bias of the side effects was not analyzed.

Fig. 7

Funnel plot


The effect size of the therapeutic effect had an SMD of 1.394 (95% CI: 0.944–1.843), which was significant for treating depression [69] and except for Garcia’s study [62], in which reporting bias was suspected because of the selection reporting, the effect size SMD was 1.074, (95% CI: 0.689–1.459), which was also a meaningful result. The studies excluded by the exclusion criteria also showed positive treatment effects of rTMS for PPD, supporting the treatment effect. In Brock’s study, 14 out of 19 patients with rTMS achieved remission [70], and in Ozmut’s study, eight out of 15 patients responded to rTMS [71]. Other studies also succeeded in improving the depression of patients with PPD using rTMS [72, 73]. It could be possible that the effect size was overestimated because the parameters that can affect the treatment effect, such as the site of stimulation, frequency, and interval time, were not established, and there was a risk of bias. However, even considering these points, the treatment potential was confirmed, and if a protocol becomes established, it is expected that more sophisticated effect sizes can be calculated.

The effect size of TMS side effects had an SMD of 0.346 (95% CI: 0.214–0.506), which was significant [69]. However, the side effects of rTMS treatment on the mothers, such as headaches, discomfort, and pain in the stimulation area, were minor, and these side effects disappeared at the end of the treatment process. Some mothers experienced supine hypotension [60], but this was caused by a posture problem during treatment and could be prevented through postural correction [68].

All children born to mothers with rTMS treatment were born healthy. In one of the RCT studies that evaluated the child’s health condition by appearance-pulse-grimace-activity-respiration scores, the difference between the two groups was not significant [experimental group 8.36 (1.50), control group 8.73 (0.90), p = 0.501] [58]. There were five preterm births and one brachial plexus injury among the fetuses. Although 5% (5) of the study participants experienced preterm birth, two of these had already been warned of the risk of preterm birth by a biomedical test. Considering that the average proportion of women who undergo preterm birth worldwide is 11% [74], it is unlikely that a causal relationship exists between rTMS and preterm birth. However, further research on this is needed. Brachial plexus injury was reported as a side effect in one newborn, but it was not related to rTMS treatment [58], and there were no other side effects in the infants. One study that checked the child of a mother treated with rTMS reported that the exposure during pregnancy did not affect the cognitive or motor development of the child [75]. High frequencies above 40 Hz affect the lungs and immune system of the fetus [76, 77], and the maximum electromagnetic field applicable to the fetus is 800 mv/m [78]. However, the frequency used in rTMS treatment is generally 1–25 Hz, and the scale of the electromagnetic field is 100 mv/m [79]. Nevertheless, additional research should be conducted because there are many aspects not yet researched.

Mothers do not prefer the current treatment for peripartum depression. They are not willing to take antidepressants because they are concerned not only about the side effects that they will suffer but also the side effects to the fetus [80, 81] Besides, 2.5% of mothers suffer from treatment-resistant depression and have to choose a different treatment method [82]. In one survey on depression treatments, only 1.2% of the population accepted ECT treatment [83]. Although the acceptance rate of rTMS was also low, when knowledge about the treatment was shared, the acceptance rate increased by more than 50%, showing the possibility as a treatment method for PPD [84].

From the side of economic efficiency, rTMS may be a good alternative for treating PPD. For example, rTMS might save $112 per quality-adjusted life years (QALY) compared to antidepressants [85] and might save $8515 per year compared to ECTs [86]. rTMS could reduce anxiety about the cost, which was one of the risk factors that had the most significant impact on pregnant women [87]. Consequently, the socioeconomic costs of peripartum depression might be reduced.

Limitation and future study direction

Regarding the limitations of the meta-analysis, our results showed high heterogeneity, and the reason may be heterogeneity due to methodological diversity because the parameters of rTMS varied from study to study, or heterogeneity due to coincidence because the analysis was conducted with small sample-sized studies. However, because the parameters vary according to the patient’s situation (e.g., the stimulation site changes according to symptoms and the frequency changes according to the stimulation site), it should be judged as clinical heterogeneity. The lack of patients and studies might also constrain our results. Thus, the effects of rTMS on PPD and should be interpreted with caution. Future research should focus on the effects in the prenatal and infancy periods and establish parameters for rTMS, such as the site stimulation or frequency.


We collected data from existing documents and identified 10 studies that were suitable for a systematic review, of which five are eligible for meta-analysis. According to the analysis of the included studies, the therapeutic effect size of rTMS for PPD showed an SMD of 1.394 (95% CI: 0.944–1.843), and the sensitivity analysis showed an SMD = 1.074 (95% CI: 0.689–1.459), which is a significant effect, but this effect size could be overestimated because more than 50% of the studies were NRS, and some studies were at risk of bias Nonetheless, rTMS seems to have potential as a treatment for peripartum depression. The side effects of rTMS for PPD had an SMD of 0.346 (95% CI: 0.214–0.506), which is meaningful. However, there were no serious side effects to the mothers or fetuses. From a variety of perspectives, the treatment of PPD using rTMS could be considered an alternative treatment to avoid exposure of the fetus to drugs and the severe side effects of ECT. Further research is required to increase the confidence in these results.

Availability of data and materials

No data or materials were generated for this narrative review.



Peripartum depression


Major depressive disorder


Electroconvulsive therapy


Monoamine oxidase


Repeated transcranial magnetic stimulation


Dorsolateral prefrontal cortex


Randomized controlled trial


Non-randomized studies


Diagnostic and Statistical Manual of Mental Disorders-5


Hamilton Depression Rating Scale


Risk of bias 2


The Risk of Bias Assessment tool for Nonrandomized Studies


Standardized Mean Deviation


Confidence interval


Montgomery-Åsberg Depression Rating Scale


Beck Depression Inventory.


Edinburgh Postnatal Depression Scale


Quality adjusted life year


Clinical Global impression scale


Global Assessment Scale


36-item Quality of Life Health Survey Vitality scores


36-item Quality of Life Health Survey Mental Health scores


  1. 1.

    Association D-AP: Diagnostic and statistical manual of mental disorders. 2013.

    Google Scholar 

  2. 2.

    Bauer A, Knapp M, Parsonage M. Lifetime costs of perinatal anxiety and depression. J Affect Disord. 2016;192:83–90.

    PubMed  Article  Google Scholar 

  3. 3.

    Schiller CE, Meltzer-Brody S, Rubinow DR. The role of reproductive hormones in postpartum depression. CNS spectrums. 2015;20(1):48–59.

    PubMed  Article  Google Scholar 

  4. 4.

    Rubio DM, Kraemer KL, Farrell MH, Day NL. Factors associated with alcohol use, depression, and their co-occurrence during pregnancy. Alcohol Clin Exp Res. 2008;32(9):1543–51.

    PubMed  PubMed Central  Article  Google Scholar 

  5. 5.

    Chang HY, Keyes KM, Lee KS, Choi IA, Kim SJ, Kim KW, Shin YH, Ahn KM, Hong SJ, Shin YJ. Prenatal maternal depression is associated with low birth weight through shorter gestational age in term infants in Korea. Early Hum Dev. 2014;90(1):15–20.

    PubMed  Article  Google Scholar 

  6. 6.

    Liu C, Cnattingius S, Bergstrom M, Ostberg V, Hjern A. Prenatal parental depression and preterm birth: a national cohort study. BJOG. 2016;123(12):1973–82.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  7. 7.

    Accortt EE, Cheadle ACD, Dunkel Schetter C. Prenatal depression and adverse birth outcomes: an updated systematic review. Matern Child Health J. 2015;19(6):1306–37.

    PubMed  PubMed Central  Article  Google Scholar 

  8. 8.

    Field T. Prenatal depression risk factors, developmental effects and interventions: A review. J Pregnancy Child Health. 2017;4(1):301.

    PubMed  PubMed Central  Article  Google Scholar 

  9. 9.

    Wichman CL, Stern TA. Diagnosing and Treating Depression During Pregnancy. Prim Care Companion CNS Disord. 2015;17(2).

  10. 10.

    Calaway K, Coshal S, Jones K, Coverdale J, Livingston R. A systematic review of the safety of electroconvulsive therapy use during the first trimester of pregnancy. J ECT. 2016;32(4):230–5.

    PubMed  Article  Google Scholar 

  11. 11.

    Eke AC, Saccone G, Berghella V. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a systematic review and meta-analysis. BJOG. 2016;123(12):1900–7.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Leiknes KA, Cooke MJ, Jarosch-von Schweder L, Harboe I, Hoie B. Electroconvulsive therapy during pregnancy: a systematic review of case studies. Arch Womens Ment Health. 2015;18(1):1–39.

    PubMed  Article  Google Scholar 

  13. 13.

    Prady SL, Hanlon I, Fraser LK, Mikocka-Walus A. A systematic review of maternal antidepressant use in pregnancy and short- and long-term offspring's outcomes. Arch Womens Ment Health. 2018;21(2):127–40.

    PubMed  Google Scholar 

  14. 14.

    Richelson E. Pharmacology of antidepressants. Mayo Clin Proc. 2001;76(5):511–27.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Stahl SM. Basic psychopharmacology of antidepressants: Part 1. Antidepressants have seven distinct mechanisms of action. J Clin Psychiatry. 1998;59(Suppl 4):5–14.

    CAS  Google Scholar 

  16. 16.

    Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D. Placental passage of antidepressant medications. Am J Psychiatr. 2003;160(5):993–6.

    PubMed  Article  Google Scholar 

  17. 17.

    Nikfar S, Rahimi R, Hendoiee N, Abdollahi M. Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: a systematic review and updated meta-analysis. Daru. 2012;20(1):75.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. 18.

    Rahimi R, Nikfar S, Abdollahi M. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reprod Toxicol. 2006;22(4):571–5.

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    Julsgaard M, Christensen LA, Gibson PR, Gearry RB, Fallingborg J, Hvas CL, Bibby BM, Uldbjerg N, Connell WR, Rosella O, et al. Concentrations of Adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016;151(1):110–9.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Huang H, Coleman S, Bridge JA, Yonkers K, Katon W. A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight. Gen Hosp Psychiatry. 2014;36(1):13–8.

    PubMed  Article  Google Scholar 

  21. 21.

    Boukhris T, Sheehy O, Mottron L, Berard A. Antidepressant use during pregnancy and the risk of autism Spectrum disorder in children. JAMA Pediatr. 2016;170(2):117–24.

    PubMed  Article  Google Scholar 

  22. 22.

    Brown AS, Gyllenberg D, Malm H, McKeague IW, Hinkka-Yli-Salomaki S, Artama M, Gissler M, Cheslack-Postava K, Weissman MM, Gingrich JA, et al. Association of Selective Serotonin Reuptake Inhibitor Exposure during Pregnancy with Speech, scholastic, and motor disorders in offspring. JAMA Psychiatry. 2016;73(11):1163–70.

    PubMed  Article  Google Scholar 

  23. 23.

    Huybrechts KF, Palmsten K, Avorn J, Cohen LS, Holmes LB, Franklin JM, Mogun H, Levin R, Kowal M, Setoguchi S. Antidepressant use in pregnancy and the risk of cardiac defects. New Engl J Med. 2014;370(25):2397–407.

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Huybrechts KF, Bateman BT, Palmsten K, Desai RJ, Patorno E, Gopalakrishnan C, Levin R, Mogun H, Hernandez-Diaz S. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA. 2015;313(21):2142–51.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  25. 25.

    Berle JØ, Spigset O. Antidepressant use during breastfeeding. Curr Womens Health Rev. 2011;7(1):28–34.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  26. 26.

    Davanzo R, Copertino M, De Cunto A, Minen F, Amaddeo A. Antidepressant drugs and breastfeeding: a review of the literature. Breastfeed Med. 2011;6(2):89–98.

    PubMed  Article  PubMed Central  Google Scholar 

  27. 27.

    Schmidt K, Olesen OV, Jensen PN. Citalopram and breast-feeding: serum concentration and side effects in the infant. Biol Psychiatry. 2000;47(2):164–5.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  28. 28.

    Lee A, Woo J, Ito S. Frequency of infant adverse events that are associated with citalopram use during breast-feeding. Am J Obstet Gynecol. 2004;190(1):218–21.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  29. 29.

    Singh A, Kar SK. How electroconvulsive therapy works?: understanding the neurobiological mechanisms. Clin Psychopharmacol Neurosci. 2017;15(3):210–21.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  30. 30.

    Balki M, Castro C, Ananthanarayan C. Status epilepticus after electroconvulsive therapy in a pregnant patient. Int J Obstet Anesth. 2006;15(4):325–8.

    CAS  PubMed  Article  Google Scholar 

  31. 31.

    Pesiridou A, Baquero G, Cristancho P, Wakil L, Altinay M, Kim D, O'Reardon JP. A case of delayed onset of threatened premature labor in association with electroconvulsive therapy in the third trimester of pregnancy. J ECT. 2010;26(3):228–30.

    PubMed  Article  Google Scholar 

  32. 32.

    Bozkurt AKT, Isintas M, Ozmenler NK, Ozsahin A, Yanarates O. Acute and maintenance electroconvulsive therapy for treatment of psychotic depression in a pregnant patient. J ECT. 2007;23(3):185–7.

    PubMed  Article  Google Scholar 

  33. 33.

    Lovas A, Almos PZ, Peto Z, Must A, Horvath S. Anesthesia for electroconvulsive therapy in early pregnancy. J ECT. 2011;27(4):328–30.

    PubMed  Article  Google Scholar 

  34. 34.

    Koren G, Nordeng H. Antidepressant use during pregnancy: the benefit-risk ratio. Am J Obstet Gynecol. 2012;207(3):157–63.

    PubMed  Article  Google Scholar 

  35. 35.

    Saatcioglu O, Tomruk NB. The use of electroconvulsive therapy in pregnancy: a review. Israel J Psychiatry Related Sci. 2011;48(1):6.

    Google Scholar 

  36. 36.

    Health Quality O. Repetitive Transcranial magnetic stimulation for treatment-resistant depression: a systematic review and Meta-analysis of randomized controlled trials. Ontario Health Technol Assess Series. 2016;16(5):1–66.

    Google Scholar 

  37. 37.

    George MS, Taylor JJ, Short EB. The expanding evidence base for rTMS treatment of depression. Curr Opin Psychiatry. 2013;26(1):13–8.

    PubMed  PubMed Central  Article  Google Scholar 

  38. 38.

    VanDerwerker CJ, Ross RE, Stimpson KH, Embry AE, Aaron SE, Cence B, George MS, Gregory CM. Combining therapeutic approaches: rTMS and aerobic exercise in post-stroke depression: a case series. Top Stroke Rehabil. 2018;25(1):61–7.

    PubMed  Article  Google Scholar 

  39. 39.

    Krepel N, Rush AJ, Iseger TA, Sack AT, Arns M. Can psychological features predict antidepressant response to rTMS? A Discovery-Replication approach. Psychol Med. 2017;50(2):264–72.

    Article  Google Scholar 

  40. 40.

    Chang D, Zhang J, Peng W, Shen Z, Gao X, Du Y, Ge Q, Song D, Shang Y, Wang Z. Smoking cessation with 20 Hz repetitive Transcranial magnetic stimulation (rTMS) applied to two brain regions: a pilot study. Front Hum Neurosci. 2018;12:344.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  41. 41.

    Voigt J, Carpenter L, Leuchter A. A systematic literature review of the clinical efficacy of repetitive transcranial magnetic stimulation (rTMS) in non-treatment resistant patients with major depressive disorder. BMC Psychiatry. 2019;19(1):13.

    PubMed  PubMed Central  Article  Google Scholar 

  42. 42.

    McNamara B, Ray J, Arthurs O, Boniface S. Transcranial magnetic stimulation for depression and other psychiatric disorders. Psychol Med. 2001;31(7):1141–6.

    CAS  PubMed  Article  Google Scholar 

  43. 43.

    KOZEL FA, GEORGE MS. Meta-analysis of left prefrontal repetitive transcranial magnetic stimulation (rTMS) to treat depression. J Psychiatric Pract. 2002;8(5):270–5.

    Article  Google Scholar 

  44. 44.

    Burt T, Lisanby SH, Sackeim HA. Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. Int J Neuropsychopharmacol. 2002;5(1):73–103.

    PubMed  Article  CAS  Google Scholar 

  45. 45.

    Konstantinou GN, Vigod SN, Mehta S, Daskalakis ZJ, Blumberger DM. A systematic review of non-invasive neurostimulation for the treatment of depression during pregnancy. J Affect Disord. 2020;272:259–68.

    PubMed  Article  Google Scholar 

  46. 46.

    Ganho-Ávila A, Poleszczyk A, Mohamed MMA, Osório A. Efficacy of rTMS in decreasing postnatal depression symptoms: a systematic review. Psychiatry Res. 2019;279:315–22.

    PubMed  Article  Google Scholar 

  47. 47.

    Felipe RM, Ferrão YA. Transcranial magnetic stimulation for treatment of major depression during pregnancy: a review. Trends Psychiatry Psychotherapy. 2016;38:190–7.

    Article  Google Scholar 

  48. 48.

    Cole J, Bright K, Gagnon L, McGirr A. A systematic review of the safety and effectiveness of repetitive transcranial magnetic stimulation in the treatment of peripartum depression. J Psychiatr Res. 2019;115:142–50.

    PubMed  Article  Google Scholar 

  49. 49.

    Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, Group P-P. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

    PubMed  PubMed Central  Article  Google Scholar 

  50. 50.

    Akl E, Altman D, Aluko P, Askie L, Beaton D, Berlin J, Bhaumik B, Bingham C, Boers M, Booth A et al: Cochrane handbook for systematic reviews of interventions; 2019.

    Google Scholar 

  51. 51.

    Spronk D, Arns M, Fitzgerald PB. Repetitive transcranial magnetic stimulation in depression: protocols, mechanisms, and new developments. In: Neurofeedback and neuromodulation techniques and applications. edn. Elsevier; 2011. p. 257–291.

  52. 52.

    Higgins JP, Sterne JA, Savovic J, Page MJ, Hróbjartsson A, Boutron I, Reeves B, Eldridge S. A revised tool for assessing risk of bias in randomized trials. Cochrane Database Syst Rev. 2016;10(Suppl 1):29–31.

    Google Scholar 

  53. 53.

    Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.

    PubMed  PubMed Central  Article  Google Scholar 

  54. 54.

    Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60–3.

    PubMed  PubMed Central  Article  Google Scholar 

  55. 55.

    Carey JC. Significance of case reports in the advancement of medical scientific knowledge. Am J Med Genet A. 2006;140(19):2131–4.

    PubMed  Article  Google Scholar 

  56. 56.

    Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.

    PubMed  PubMed Central  Article  Google Scholar 

  57. 57.

    Becker BJ. Synthesizing standardized mean-change measures. Br J Math Stat Psychol. 1988;41(2):257–78.

    Article  Google Scholar 

  58. 58.

    Kim DR, Wang E, McGeehan B, Snell J, Ewing G, Iannelli C, O'Reardon JP, Sammel MD, Epperson CN. Randomized controlled trial of transcranial magnetic stimulation in pregnant women with major depressive disorder. Brain Stimul. 2019;12(1):96–102.

    PubMed  Article  Google Scholar 

  59. 59.

    Myczkowski ML, Dias AM, Luvisotto T, Arnaut D, Bellini BB, Mansur CG, Renno J, Tortella G, Ribeiro PL, Marcolin MA. Effects of repetitive transcranial magnetic stimulation on clinical, social, and cognitive performance in postpartum depression. Neuropsychiatr Dis Treat. 2012;8:491–500.

    PubMed  PubMed Central  Article  Google Scholar 

  60. 60.

    Kim DR, Epperson N, Pare E, Gonzalez JM, Parry S, Thase ME, Cristancho P, Sammel MD, O'Reardon JP. An open label pilot study of transcranial magnetic stimulation for pregnant women with major depressive disorder. J Women's Health (Larchmt). 2011;20(2):255–61.

    Article  Google Scholar 

  61. 61.

    Hizli Sayar G, Ozten E, Tufan E, Cerit C, Kagan G, Dilbaz N, Tarhan N. Transcranial magnetic stimulation during pregnancy. Arch Womens Ment Health. 2014;17(4):311–5.

    PubMed  Article  Google Scholar 

  62. 62.

    Garcia KS, Flynn P, Pierce KJ, Caudle M. Repetitive transcranial magnetic stimulation treats postpartum depression. Brain Stimul. 2010;3(1):36–41.

    PubMed  Article  Google Scholar 

  63. 63.

    Zhang X, Liu K, Sun J, Zheng Z. Safety and feasibility of repetitive transcranial magnetic stimulation (rTMS) as a treatment for major depression during pregnancy. Arch Womens Ment Health. 2010;13(4):369–70.

    PubMed  Article  Google Scholar 

  64. 64.

    Tan O, Tarhan N, Coban A, Baripoglu SK, Guducu F, Izgi HB, Hizli G, Ates O, Bulut H. Antidepressant effect of 58 sessions of rTMS in a pregnant woman with recurrent major depressive disorder: a case report. Prim Care Companion J Clin Psychiatry. 2008;10(1):69–71.

    PubMed  PubMed Central  Article  Google Scholar 

  65. 65.

    Ferrao YA, RdMFd S. Repetitive transcranial magnetic stimulation for the treatment of major depression during pregnancy. Braz J Psychiatry. 2018;40(1):227–8.

    PubMed  PubMed Central  Article  Google Scholar 

  66. 66.

    Cohen RB, Ferreira MS, Ferreira MJ, Fregni F. Use of repetitive transcranial magnetic stimulation for the management of bipolar disorder during the postpartum period. Brain Stimulation. 2008;1(3):224–6.

    PubMed  Article  Google Scholar 

  67. 67.

    Klírová M, Novak T, Kopecek M, Mohr P, Strunzova V. Repetitive transcranial magnetic stimulation (rTMS) in major depressive episode during pregnancy. Neuro Endocrinol Letters. 2008;29:69–70.

    Google Scholar 

  68. 68.

    Kim DR, Wang E. Prevention of supine hypotensive syndrome in pregnant women treated with transcranial magnetic stimulation. Psychiatry Res. 2014;218(1–2):247–8.

    PubMed  PubMed Central  Article  Google Scholar 

  69. 69.

    Cohen J. Statistical power analysis for the behavioral sciences: academic press; 2013.

    Google Scholar 

  70. 70.

    Brock DG, Demitrack MA, Groom P, Holbert R, Rado JT, Gross PK, Goethe JW, Schrodt GR, Weeks HR. Effectiveness of NeuroStar transcranial magnetic stimulation (TMS) in patients with major depressive disorder with postpartum onset. Brain Stimul Basic Transl Clin Res Neuromodul. 2016;9(5):e7.

    Google Scholar 

  71. 71.

    Ozmut O, Balibey H, Yilan Y, Algul A, Ebrinc S, Cetin M, Tutuncu R, Ates A, Basoglu C. Repetitive transcranial magnetic stimulation for the treatment of depression during pregnancy and postpartum period. Bull Clin Psychopharmacol. 2015;25(1):S203–4.

    Google Scholar 

  72. 72.

    Stultz DJ, Thistlethwaite D, Voltin R, Osburn S, Walton R, Burns T. Bipolar, depressed, and pregnant – transcranial magnetic stimulation as a treatment alternative. Brain Stimul Basic Transl Clin Res Neuromodul. 2018;11(6):e15.

    Google Scholar 

  73. 73.

    Xiong W, Lopez R, Cristancho P. Transcranial magnetic stimulation in the treatment of peripartum bipolar depression: a case report. Rev Bras Psiquiatria. 2018;40(3):344–5.

    Article  Google Scholar 

  74. 74.

    Walani SR. Global burden of preterm birth. Int J Gynecol Obstet. 2020;150(1):31–3.

    Article  Google Scholar 

  75. 75.

    Eryılmaz G, Sayar GH, Özten E, Gül IG, Yorbik Ö, Işiten N, Bağcı E. Follow-up study of children whose mothers were treated with transcranial magnetic stimulation during pregnancy: preliminary results. Neuromodulation. 2015;18(4):255–60.

    PubMed  Article  Google Scholar 

  76. 76.

    Bracken MB, Belanger K, Cookson WO, Triche E, Christiani DC, Leaderer BP. Genetic and perinatal risk factors for asthma onset and severity: a review and theoretical analysis. Epidemiol Rev. 2002;24(2):176–89.

    PubMed  Article  Google Scholar 

  77. 77.

    Li DK, Chen H, Odouli R. Maternal exposure to magnetic fields during pregnancy in relation to the risk of asthma in offspring. Arch Pediatr Adolesc Med. 2011;165(10):945–50.

    PubMed  Article  Google Scholar 

  78. 78.

    Allen CH, Kluger BM, Buard I. Safety of Transcranial magnetic stimulation in children: a systematic review of the literature. Pediatr Neurol. 2017;68:3–17.

    PubMed  PubMed Central  Article  Google Scholar 

  79. 79.

    Yanamadala J, Noetscher GM, Makarov SN, Pascual-Leone A. Estimates of peak electric fields induced by Transcranial magnetic stimulation in pregnant women as patients using an FEM full-body model. In: 2017 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC): 11–15 July 2017 2017; 2017. p. 1441–4.

    Google Scholar 

  80. 80.

    O'Mahen HA, Flynn HA. Preferences and perceived barriers to treatment for depression during the perinatal period. J Women's Health. 2008;17(8):1301–9.

    Article  Google Scholar 

  81. 81.

    Goodman JH. Women’s attitudes, preferences, and perceived barriers to treatment for perinatal depression. Birth. 2009;36(1):60–9.

    PubMed  Article  Google Scholar 

  82. 82.

    Cepeda MS, Kern DM, Nicholson S. Treatment resistant depression in women with peripartum depression. BMC Pregnancy Childbirth. 2019;19(1):323.

    PubMed  PubMed Central  Article  Google Scholar 

  83. 83.

    Maughan D, Molodynski A. An international perspective on the acceptability and sustainability of electroconvulsive therapy. BJPsych Int. 2016;13(1):10–2.

    PubMed  PubMed Central  Article  Google Scholar 

  84. 84.

    Kim DR, Sockol L, Barber JP, Moseley M, Lamprou L, Rickels K, O'Reardon JP, Epperson CN. A survey of patient acceptability of repetitive transcranial magnetic stimulation (TMS) during pregnancy. J Affect Disord. 2011;129(1–3):385–90.

    PubMed  Article  Google Scholar 

  85. 85.

    Simpson KN, Welch MJ, Kozel FA, Demitrack MA, Nahas Z. Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis. Adv Ther. 2009;26(3):346–68.

    PubMed  Article  Google Scholar 

  86. 86.

    Zhao YJ, Tor PC, Khoo AL, Teng M, Lim BP, Mok YM. Cost-effectiveness modeling of repetitive Transcranial magnetic stimulation compared to electroconvulsive therapy for treatment-resistant depression in Singapore. Neuromodulation. 2018;21(4):376–82.

    PubMed  Article  Google Scholar 

  87. 87.

    Lancaster CA, Gold KJ, Flynn HA, Yoo H, Marcus SM, Davis MM. Risk factors for depressive symptoms during pregnancy: a systematic review. Am J Obstet Gynecol. 2010;202(1):5–14.

    PubMed  PubMed Central  Article  Google Scholar 

Download references


We would like to thank the Korea Health Industry Development Institute (KHIDI) for supporting the training program for advanced medical device industry professionals.


No funding was obtained for this study.

Author information




HJ: Conceive the project, search strategy, screening literature, data extraction, bias evaluation, data analysis, and drafting the manuscript and revising JY: Study design, screening literature, bias evaluation, data analysis, drafting the manuscript, and revising the manuscript and SMK supervised the entire procedures and helped to draft the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Ji Yean Kwon.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Appendix 1.

Excluded literature and the reason.

Additional file 2: Appendix 2.

Risk assessment of selected literature.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lee, H.J., Kim, S.M. & Kwon, J.Y. Repetitive transcranial magnetic stimulation treatment for peripartum depression: systematic review & meta-analysis. BMC Pregnancy Childbirth 21, 118 (2021).

Download citation


  • Repetitive transcranial magnetic stimulation
  • rTMS
  • Peripartum depression
  • Pregnancy